Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway

Fig. 3

CXCL1 is critical for Topoisomerase inhibitors-promoted cancer cell migration and invasion. a Validation of the efficiency of CXCL1 knockdown after transfection with different siRNAs for 48 h (left two panels) or siRNA #1 for 48 and 72 h (right two panels). b CXCL1 knockdown prevented TI-promoted motility. After siRNA transfection for 24 h, cells were subjected to migration or invasion assay for 24 h in the presence of VP-16 (20 μM) or CPT-11 (80 μg/ml). c Neutralization of CXCL1 prevented TI-promoted motility. Cells were subjected to migration or invasion assay for 24 h in the presence of VP-16 (20 μM) or CPT-11 (80 μg/ml) plus 5 μg/ml of anti-CXCL1 or IgG

Back to article page